A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia

• Status: Terminated
• Trial end date: 2017-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a multicenter, randomized, double-blind, parallel-group, active controlled comparative study of the safety and efficacy of 2 dosing regimens of FV-100 versus valacyclovir administered for 7 days in subjects with uncomplicated AHZ(acute herpes zoster).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ContraVir Pharmaceuticals, Inc.
• Treatments: Acyclovir; Antiviral Agents; Valacyclovir

Criteria

Inclusion Criteria:

• Receive a clinical diagnosis of uncomplicated AHZ as evidenced by a unilateral dermatomal rash

• Have zoster-related pain

• Are able to be randomized and receive their first dose within approximately 120 hours from appearance of rash

Exclusion Criteria:

• Have multidermal or disseminated AHZ

• Have facial, ophthalmologic or oral manifestations

• Have received Zostavax